RecruitingPhase 1NCT06349473
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Studying Congenital factor VII deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Equilibra Bioscience LLC
- Intervention
- SR604(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2024 – 2026
Study locations (10)
- California Clinical Trials Medical Group (CCTMG), Glendale, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- LA Center for Bleeding and Clotting Disorders - Metairie, Metairie, Louisiana, United States
- University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States
- Penn State Milton S Hershey Medical Center Pediatrics, Hershey, Pennsylvania, United States
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia, Pennsylvania, United States
- McMaster University Medical Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06349473 on ClinicalTrials.govOther trials for Congenital factor VII deficiency
Additional recruiting or active studies for the same condition.